A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab

A 61-year-old male, who had been admitted to another hospital due to disseminated intravascular coagulation (DIC), was referred to our hospital. Total colonoscopy, abdominal dynamic CT and positron-emission tomography revealed bone metastasis and multiple lymphocytic metastases from transverse colon...

Descripción completa

Detalles Bibliográficos
Autores principales: Naito, Masayasu, Yoshida, Yoichiro, Aisu, Naoya, Tanimura, Shu, Hoshino, Seiichiro, Tanaka, Toshihiro, Nimura, Satoshi, Tamura, Kazuo, Yamashita, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: July, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130823/
https://www.ncbi.nlm.nih.gov/pubmed/25126072
http://dx.doi.org/10.1159/000365001
_version_ 1782330377577168896
author Naito, Masayasu
Yoshida, Yoichiro
Aisu, Naoya
Tanimura, Shu
Hoshino, Seiichiro
Tanaka, Toshihiro
Nimura, Satoshi
Tamura, Kazuo
Yamashita, Yuichi
author_facet Naito, Masayasu
Yoshida, Yoichiro
Aisu, Naoya
Tanimura, Shu
Hoshino, Seiichiro
Tanaka, Toshihiro
Nimura, Satoshi
Tamura, Kazuo
Yamashita, Yuichi
author_sort Naito, Masayasu
collection PubMed
description A 61-year-old male, who had been admitted to another hospital due to disseminated intravascular coagulation (DIC), was referred to our hospital. Total colonoscopy, abdominal dynamic CT and positron-emission tomography revealed bone metastasis and multiple lymphocytic metastases from transverse colon cancer in addition to disseminated carcinomatosis of the bone marrow (DCBM). We immediately performed chemotherapy with XELOX + bevacizumab and denosumab against DCBM from transverse colon cancer in order to avoid radical surgery. In addition, we initiated the administration of recombinant human soluble thrombomodulin for 1 week to treat DIC. The patient was able to tolerate and receive 4 cycles of chemotherapy without any severe side effects. After receiving the 4 cycles of treatment, he recovered from DIC, and the bone and multiple lymphocytic metastases disappeared.
format Online
Article
Text
id pubmed-4130823
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-41308232014-08-14 A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab Naito, Masayasu Yoshida, Yoichiro Aisu, Naoya Tanimura, Shu Hoshino, Seiichiro Tanaka, Toshihiro Nimura, Satoshi Tamura, Kazuo Yamashita, Yuichi Case Rep Oncol Published online: July, 2014 A 61-year-old male, who had been admitted to another hospital due to disseminated intravascular coagulation (DIC), was referred to our hospital. Total colonoscopy, abdominal dynamic CT and positron-emission tomography revealed bone metastasis and multiple lymphocytic metastases from transverse colon cancer in addition to disseminated carcinomatosis of the bone marrow (DCBM). We immediately performed chemotherapy with XELOX + bevacizumab and denosumab against DCBM from transverse colon cancer in order to avoid radical surgery. In addition, we initiated the administration of recombinant human soluble thrombomodulin for 1 week to treat DIC. The patient was able to tolerate and receive 4 cycles of chemotherapy without any severe side effects. After receiving the 4 cycles of treatment, he recovered from DIC, and the bone and multiple lymphocytic metastases disappeared. S. Karger AG 2014-07-02 /pmc/articles/PMC4130823/ /pubmed/25126072 http://dx.doi.org/10.1159/000365001 Text en Copyright © 2014 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: July, 2014
Naito, Masayasu
Yoshida, Yoichiro
Aisu, Naoya
Tanimura, Shu
Hoshino, Seiichiro
Tanaka, Toshihiro
Nimura, Satoshi
Tamura, Kazuo
Yamashita, Yuichi
A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab
title A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab
title_full A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab
title_fullStr A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab
title_full_unstemmed A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab
title_short A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab
title_sort report of disseminated carcinomatosis of the bone marrow originating from transverse colon cancer successfully treated with chemotherapy using xelox plus bevacizumab
topic Published online: July, 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130823/
https://www.ncbi.nlm.nih.gov/pubmed/25126072
http://dx.doi.org/10.1159/000365001
work_keys_str_mv AT naitomasayasu areportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT yoshidayoichiro areportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT aisunaoya areportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT tanimurashu areportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT hoshinoseiichiro areportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT tanakatoshihiro areportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT nimurasatoshi areportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT tamurakazuo areportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT yamashitayuichi areportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT naitomasayasu reportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT yoshidayoichiro reportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT aisunaoya reportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT tanimurashu reportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT hoshinoseiichiro reportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT tanakatoshihiro reportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT nimurasatoshi reportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT tamurakazuo reportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab
AT yamashitayuichi reportofdisseminatedcarcinomatosisofthebonemarroworiginatingfromtransversecoloncancersuccessfullytreatedwithchemotherapyusingxeloxplusbevacizumab

Ejemplares similares